Thallion will present a comprehensive poster and abstract on the safety and efficacy data from the recently completed ECO-4601 Phase I/II trial on Thursday, November 15th at a joint meeting of the 4th International Society of Chemotherapy, Infection and Cancer International Conference on Cancer Therapeutics and the 7th Princess Margaret Hospital Conference: New Developments in Cancer Management in Toronto. The presentation will take place at the Metro Toronto Convention Center, Room 716, starting at 5:20 pm. Thallion's poster and abstract, reference number P-0035, are titled: Safety and efficacy of ECO-4601, a novel Ras/MAPK pathway inhibitor & PBR targeting agent, in a Phase I clinical trial.
Thallion will also present a second poster and abstract based on studies evaluating ECO-4601 in an animal model of cancer titled, Targeted Delivery of ECO-4601 to Brain Tumours in an Orthotopic Model, at the 3rd Modern Drug Discovery & Development Summit in San Francisco. The poster session presentation will take place at the Hyatt Regency San Francisco Airport Hotel on November 28th at 5:15pm.
About ECO-4601
ECO-4601 is a novel small molecule derived from a nonpathogenic microorganism. It has demonstrated broad in vitro cytotoxic activity across a diverse panel of tumour cell lines and in vivo efficacy in a number of xenograft tumour models. Preclinical data suggest that ECO-4601 is a targeted anti-cancer agent with dual activity: selective binding to the peripheral benzodiazepine receptor (PBR) and inhibition of the Ras/MAPK pathway. Thallion has successfully completed the recruitment and administration of the extension phase of its ECO-4601 Phase I/II clinical trial. ECO-4601 was discovered using DECIPHER®, Thallion's proprietary genomics-based drug discovery platform.
About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (Toronto:TLN.TO - News) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Thallion has three active clinical programs at a Phase II, or later, stage of development which include: Shigamabs®, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections; ECO-4601, a novel anti-cancer therapy derived from a nonpathogenic microorganism; and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. Additional information about the Company can be obtained at www.thallion.com.
Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.
Contact: Contacts: Thallion Pharmaceuticals Inc. Michael Singer Chief Financial Officer (514-940-3600 (514-228-3622 (FAX) info@thallion.com http://www.thallion.com
The Equicom Group Inc. Ross Marshall Investor Relations 416-815-0700 (Ext. 238) 416-815-0080 (FAX) rmarshall@equicomgroup.com
Source: Thallion Pharmaceutiques Inc.
